Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine whether replacing leptin to normal levels can reverse
the changes in fat distribution, lipid profile, and other metabolic problems associated with
highly active antiretroviral therapy (HAART)-induced lipodystrophy and metabolic syndrome in
HIV patients.
Phase:
Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
Amgen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)